The human gastrointestinal tract is populated with a diverse microbial community. The vast
genetic and metabolic potential of the gut microbiome underpins its ubiquity in nearly every …

Highly reproducible epidemiological evidence shows that type 2 diabetes (T2D) increases
the risk and rate of progression of Parkinson's disease (PD), and crucially, the repurposing …

The incidence of type 2 diabetes mellitus (T2DM) has increased in our society in recent
decades as the population ages, and this trend is not expected to revert. This is the same for …

Neurodegenerative diseases have reached alarming numbers in the past decade.
Unfortunately, clinical trials testing potential therapeutics have proven futile. In the absence …

Metformin is a first-line drug for treating type 2 diabetes mellitus (T2DM) and one of the most
commonly prescribed drugs in the world. Besides its hypoglycemic effects, metformin also …

The recent validation of the α-synuclein seed amplification assay as a biomarker with high
sensitivity and specificity for the diagnosis of Parkinson's disease has formed the backbone …

Traditional drug development in Parkinson's disease (PD) faces significant challenges
because of its protracted timeline and high costs. In response, innovative master protocols …

Cholecystokinin (CCK) is a neuropeptide modulating digestion, glucose levels,
neurotransmitters and memory. Recent studies suggest that CCK exhibits neuroprotective …

Background Previous studies reported inconsistent results regarding association between
diabetes mellitus (DM), prediabetes and risk, disease progression of Parkinson's disease …

About 10% of the adult population is living with type 2 diabetes mellitus (T2DM) and 1% of
the population over 60 years of age is suffering from Parkinson's disease (PD). A school of …